Clinical TrialJul 31, 2026, 07:04 AM
Tiziana Life Sciences' Foralumab Reduces Neuroinflammation up to 34% in MSA
AI Summary
Tiziana Life Sciences announced positive quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in its Phase 2 clinical trial for intranasal foralumab. The patient demonstrated up to a 34% reduction in standardized uptake value (SUV) and 26% reduction in standardized uptake value ratio (SUVR) in affected brain regions, indicating reduced inflammatory activity. These consistent findings, similar to the first two patients, strengthen confidence in foralumab's potential to address neuroinflammation in MSA, a disease with no approved treatments.
Key Highlights
- Third MSA patient in Phase 2 trial showed up to 34% reduction in SUV.
- Third MSA patient also showed up to 26% reduction in SUVR in affected brain regions.
- These findings are consistent with the first two MSA patients in the trial.
- First two MSA patients showed up to 35% SUV reduction and 24% SUVR reduction.
- Intranasal foralumab is a fully human anti-CD3 monoclonal antibody.
- Foralumab is also being studied in Phase 2a for non-active secondary progressive multiple sclerosis.
- Multiple System Atrophy (MSA) currently has no approved disease-modifying treatments.
Price Impact
More from TLSA